U24CA264027

Pathway, network, and spatiotemporal integration of cancer genomics data - project summary.

Cancer sequencing projects have demonstrated that tumors are tremendously heterogeneous, reflecting the large diversity of perturbations in the cellular machinery that promote tumor growth and metastasis. Tumors from different patients with the same type of cancer have a diverse collection of genomic, epigenomic, and transcriptomic aberrations.

Moreover, a tumor from a single patient is a mixture of cell types including normal cells, stroma, and multiple subpopulations of cancerous cells. We propose a Genome Data Analysis Center (GDAC) that will develop and apply novel computational approaches to address the challenges of inter-tumor and intra-tumor heterogeneity.

This GDAC will integrate data from multiple genome characterization platforms, multiple sequencing technologies -- including bulk, single-cell, and spatial sequencing technologies – and leverage prior knowledge of pathways and interaction networks to explain clinical phenotypes and inform treatment strategies.

The GDAC will perform pathway and network integration of genome characterization data, spatial analysis of tumor microenvironment, and temporal analysis of intra-tumor heterogeneity, tumor evolution, and network rewiring. These analyses will enable more precise translation of cancer genome characterization efforts into clinical utility for a larger fraction of cancer patients.

The GDAC will continue the ongoing contributions of the PIs to the current Genome Data Analysis Network (GDAN) and previous efforts in The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) projects.

The Trustees Of Princeton University

TO IMPROVE SCREENING AND EARLY DETECTION STRATEGIES AND TO DEVELOP ACCURATE DIAGNOSTIC TECHNIQUES AND METHODS FOR PREDICTING THE COURSE OF DISEASE IN CANCER PATIENTS. SCREENING AND EARLY DETECTION RESEARCH INCLUDES DEVELOPMENT OF STRATEGIES TO DECREASE CANCER MORTALITY BY FINDING TUMORS EARLY WHEN THEY ARE MORE AMENABLE TO TREATMENT. DIAGNOSIS RESEARCH FOCUSES ON METHODS TO DETERMINE THE PRESENCE OF A SPECIFIC TYPE OF CANCER, TO PREDICT ITS COURSE AND RESPONSE TO THERAPY, BOTH A PARTICULAR THERAPY OR A CLASS OF AGENTS, AND TO MONITOR THE EFFECT OF THE THERAPY AND THE APPEARANCE OF DISEASE RECURRENCE. THESE METHODS INCLUDE DIAGNOSTIC IMAGING AND DIRECT ANALYSES OF SPECIMENS FROM TUMOR OR OTHER TISSUES. SUPPORT IS ALSO PROVIDED FOR ESTABLISHING AND MAINTAINING RESOURCES OF HUMAN TISSUE TO FACILITATE RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.396 - Cancer Biology Research

National Cancer Institute (NCI) [HHS - NIH]

Princeton, New Jersey 08543 United States

Single Zip Code

Genomic Data Analysis Network: Genomic Data Center (U24 Clinical Trial Not Allowed) (RFA-CA-20-053)

Amendment Since initial award the total obligations have increased 292% from $307,697 to $1,207,662.